Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WINK study of infliximab withdrawal guided by pharmacokinetics in inflammatory bowel disease remission
NL-OMON49879Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease, sponsored by University Medical Center Utrecht. Primary endpoints: Interindividual variation in pharmacokinetic parameters and Relapse rate after withdrawal of anti-TNF within one year. Started Dec 2019; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON49879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49879.